MiR-200c has been described as a powerful master regulator of epithelial-to-mesenchymal transition in breast and ovarian cancer cells through altering the expression of ZEB1 and E-cadherin by binding to 3’ UTRs and driving degradation or blocking translation of the target mRNA [11-14]. The gene discussed is ZEB1; the disease is ovarian carcinoma.